Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 219 results found since Jan 2013.
Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics
Atrial fibrillation (AF) confers the major risk for ischemic stroke and systemic embolism [1]. Although anticoagulants can reduce the risk of AF-associated stroke, thromboembolic events, and mortality [2,3], a major drawback is the increased the risk of bleeding [4,5]. The overall risks and benefits must be carefully considered when selecting the most appropriate antithrombotic therapy, and for this reason, accurate bleeding risk stratification is needed. In clinical practice, various bleeding risk scores have been proposed and validated to assess the risk of bleeding in AF patients receiving oral anticoagulants (OAC).
Source: Thrombosis Research - November 8, 2021 Category: Hematology Authors: Sun Young Choi, Moo Hyun Kim, Sung-Cheol Yun Tags: Letter to the Editors-in-Chief Source Type: research
Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy
Aspirin non-response due to persistent platelet reactivity has been associated with adverse vascular events. Light transmission aggregometry (LTA), the ‘gold standard’ for measuring the platelet response to aspirin therapy, is a cumbersome procedure and a simple and reliable alternative is required. Our aim was to explore whether serum thromboxane B2 (sTXB2) and soluble P-selectin can be used to identify patients who are at risk of increased pl atelet reactivity while on aspirin.
Source: Thrombosis Research - October 28, 2021 Category: Hematology Authors: Pandarisamy Sundaravadivel, Rita Christopher, Nitin C. Ramanujam, Sadanandavalli Retnaswami Chandra Tags: Full Length Article Source Type: research
Novel prenatal diagnosis of protein C deficiency and primary prophylaxis with protein C concentrate
Protein C deficiency (PCD) is a rare inherited thrombophilia with high morbidity and mortality. Protein C plays an important role in the coagulation cascade by inactivating factors V and VIII, which then decreases thrombin production. In the absence of protein C, these pro-coagulant factors proceed unchecked, causing a hypercoagulable state. PCD may manifest with early and severe clinical complications, including purpura fulminans, disseminated intravascular coagulation, vitreal vein thrombosis resulting in blindness, and arterial ischemic stroke [1].
Source: Thrombosis Research - October 19, 2021 Category: Hematology Authors: Alexandra Prosser, Lauren Amos, Mukta Sharma Tags: Full Length Article Source Type: research
Association of antithrombotic medications and composition of thrombi retrieved by mechanical thrombectomy in acute ischemic stroke
Timely restoration of blood perfusion through thrombolysis and/or mechanical thrombectomy (MT) is an important step in salvaging ischemic brain in stroke patients. MT has opened an avenue for histological evaluation of thrombi and over the last couple of years our knowledge on the thromboembolus histological and mechanical properties and effects of these properties on the success of MT has grown significantly [1,2]. Two major classes of antithrombotic therapies, including antiplatelet and anticoagulant drugs, have been used for both management and prevention of stroke.
Source: Thrombosis Research - September 26, 2021 Category: Hematology Authors: Mehdi Abbasi, Oana Madalina Mereuta, Sean F. Fitzgerald, Daying Dai, Alejandro A. Rabinstein, Ramanathan Kadirvel, David F. Kallmes, Waleed Brinjikji Tags: Letter to the Editors-in-Chief Source Type: research
Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism
Anticoagulation therapy, especially using heparin or recently developed oral direct factor Xa inhibitors (DiXals), is recommended as first-line treatment for cancer-related venous thromboembolism (VTE). However, the preventive efficacy of these anticoagulants for cancer-associated ischemic stroke is still unknown. We retrospectively investigated the efficacy of subcutaneous unfractionated heparin (UFH) and DiXals for preventing the recurrence of cancer-associated cryptogenic ischemic stroke with VTE.
Source: Thrombosis Research - August 23, 2021 Category: Hematology Authors: Genpei Yamaura, Takeshi Ito, Yosuke Miyaji, Naohisa Ueda, Yoshiharu Nakae, Takayuki Momoo, Tatsu Nakano, Yuji Johmura, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Hideyuki Takeuchi, Tatsuya Takahashi, Shigeru Koyano, Shigeki Yamaguchi, Mutsumi Yokoyama, Source Type: research
Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia
Due to advancements in hemophilia care, the overall life expectancy of persons with hemophilia is almost approaching that of the general population [1]. As a result, a growing population of elderly hemophilia patients is now prone to the same age-related cardiovascular comorbidities, such as coronary artery disease (CAD) and atrial fibrillation (AF) [2,3]. The management of AF is a challenge as antithrombotic therapy, the standard of care, is usually contraindicated in persons with hemophilia. Left atrial appendage occlusion (LAAO) is an alternative option for stroke prevention in patients with AF with a contraindication t...
Source: Thrombosis Research - August 4, 2021 Category: Hematology Authors: Ming Y. Lim, Mouhamed Yazan Abou-Ismail Tags: Letter to the Editors-in-Chief Source Type: research
Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil
Oral anticoagulation (OA) is a well-established therapeutic approach for prevention of cardioembolic stroke and venous thromboembolism [1]. Adequate OA is a key element in reducing the high social burden, morbidity and mortality associated with cardiovascular diseases [2 –4]. In January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. Since then, the strategy of social distancing has been adopted in most countries, with varying degrees of restriction and compliance.
Source: Thrombosis Research - July 9, 2021 Category: Hematology Authors: Kendra Lys Calixto Machado, Suzana Tanquella da Rosa, Soraya Dobner, Ivan Schneider Boettcher, Gilberto Comaru Pasqualotto, Adelina Elisabeth Lehmkuhl Lopes, Tain á de Araújo, Lysandra Patricia Luchtenberg Bolduan, Maria Daniela Holthausen Perico Colomb Tags: Letter to the Editors-in-Chief Source Type: research
Maximum intravenous Alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes
We examined differences between patients treated with WBD vs. MD.
Source: Thrombosis Research - June 6, 2021 Category: Hematology Authors: Kaushik Ravipati, Roboan Guillen, Starlie Belnap, Anshul Saxena, Emir Veledar, Amy K. Starosciak, Felipe De Los Rios La Rosa Source Type: research
Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research
Not all patent foramen ovales are alike!
We read with great interest the elegant investigation by Lacut et al., based on RIETE registry, demonstrating that patent foramen ovale (PFO) in patients with acute pulmonary embolism (PE) is under-diagnosed and associated with a higher risk of ischemic stroke compared to those without PFO [1]. to Although the results of this study are interesting and a significant contribution to the management of acute PE, the role of PFO in such study population should be cautiously considered since the study did not provide any anatomical and/or functional PFO characterization.
Source: Thrombosis Research - May 5, 2021 Category: Hematology Authors: Gianluca Rigatelli, Marco Zuin Tags: Letter to the Editors-in-Chief Source Type: research
Thrombin generation is associated with ischemic stroke at a young age
Understanding the underlying mechanisms in ischemic stroke (IS) in young adults remains challenging. Thrombin activates processes that contribute to the development and progression of arterial diseases. We investigated the association between thrombin generation (TG) and a first IS or transient ischemic attack (TIA) in young adults.
Source: Thrombosis Research - March 29, 2021 Category: Hematology Authors: Samantha J. Donkel, Karmen Pater, Frank W.J. Leebeek, Diederik W.J. Dippel, Hugo ten Cate, Moniek P.M. de Maat Source Type: research
Outcomes in patients with acute pulmonary embolism and patent foramen ovale: Findings from the RIETE registry
An increased risk of ischemic stroke in patients with acute pulmonary embolism (PE) and patent foramen ovale (PFO) was reported but few data exist regarding prognostic outcomes of those patients.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: K. Lacut, E. Le Moigne, F. Couturaud, C. Font, F.J. V ázquez, I. Cañas, J.A. Díaz-Peromingo, A. Gil-Díaz, E. Bucherini, M. Monreal, the RIETE investigators Tags: Full Length Article Source Type: research
5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselected cohorts.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf Tags: Full Length Article Source Type: research
Peak plasma rivaroxaban levels in patients weighing 120 kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research
Peak plasma rivaroxaban levels in patients weighing 120 kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research
